EUVIMEDEUVIMED entdecken
Validierungsstudie

The European Network for the Study of Adrenal Tumors Staging System (2015): A United States Validation

Letizia Maria Ippolita Jannello iD, Reha-Baris Incesu iD, Simone Morra, Lukas Scheipner iD, Andrea Baudo iD, Mario de Angelis, Carolin Siech iD, Zhe Tian, Jordan A Goyal, Stefano Luzzago iD, Francesco A Mistretta, Matteo Ferro und 11 weitere

The Journal of Clinical Endocrinology & Metabolism · 15.10.2024 · 109 (11) · e2084-e2089

DOI: 10.1210/clinem/dgae047 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 24.01.2024. Verfasst von Letizia Maria Ippolita Jannello und 22 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, H2X 0A9, Canada. Hauptthemen laut MEDLINE: Neoplasm Staging, SEER Program, Adrenocortical Carcinoma, Adrenal Cortex Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To test the ability of the 2015 modified version of the European Network for the Study of Adrenal Tumors staging system (mENSAT) in predicting cancer-specific mortality (CSM), as well as overall mortality (OM) in adrenocortical carcinoma (ACC) patients of all stages, in a large-scale, and contemporary United States cohort.

Methods

We relied on the Surveillance, Epidemiology, and End Results (SEER) database (2004–2020) to test the accuracy and calibration of the mENSAT and subsequently compared it to the 8th edition of the American Joint Committee on Cancer staging system (AJCC).

Results

In 858 ACC patients, mENSAT accuracy was 74.7% for 3-year CSM predictions and 73.8% for 3-year OM predictions. The maximum departures from ideal predictions in mENSAT were +17.2% for CSM and +11.8% for OM. Conversely, AJCC accuracy was 74.5% for 3-year CSM predictions and 73.5% for 3-year OM predictions. The maximum departures from ideal predictions in AJCC were −6.7% for CSM and −7.1% for OM.

Conclusion

The accuracy of mENSAT is virtually the same as that of AJCC in predicting CSM (74.7% vs 74.5%) and OM (73.7% vs 73.5%). However, calibration is lower for mENSAT than for AJCC. In consequence, no obvious benefit appears to be associated with the use of mENSAT relative to AJCC in US ACC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm StagingSEER ProgramAdrenocortical CarcinomaAdrenal Cortex NeoplasmsHumansUnited StatesMaleFemaleMiddle AgedAgedAdultPrognosisAdrenal Gland NeoplasmsEurope

Stichwörter der Autor:innen

adrenocortical carcinomaexternal validationprognostic modelstaging system

Autor:innen und Institutionen

  • Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, H2X 0A9, Canada.
  • Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, 20141, Italy.
  • Department of Urology, Università degli Studi di Milano, Milan, 20122, Italy.
  • Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, 20251, Germany.
  • Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, 80131, Italy.
  • Department of Urology, Medical University of Graz, Graz, 8010, Austria.

ORCID-Profile: Letizia Maria Ippolita Jannello, Reha-Baris Incesu, Lukas Scheipner, Andrea Baudo, Carolin Siech, Stefano Luzzago, Fred Saad, Shahrokh F Shariat, Felix K H Chun, Alberto Briganti, Derya Tilki, Sascha Ahyai, Luca Carmignani, Ottavio de Cobelli, Gennaro Musi, Pierre I Karakiewicz

Zitieren

APA

Jannello, L. M. I., Incesu, R. B., Morra, S., Scheipner, L., Baudo, A., de Angelis, M., Siech, C., Tian, Z., Goyal, J. A., Luzzago, S., Mistretta, F. A., Ferro, M., Saad, F., Shariat, S. F., Chun, F. K. H., Briganti, A., Tilki, D., Ahyai, S., Carmignani, L., …, & Karakiewicz, P. I. (2024). The European Network for the Study of Adrenal Tumors Staging System (2015): A United States Validation. The Journal of Clinical Endocrinology & Metabolism, 109(11), e2084-e2089. https://doi.org/10.1210/clinem/dgae047

Vancouver

Jannello LMI, Incesu RB, Morra S, Scheipner L, Baudo A, de Angelis M, et al. The European Network for the Study of Adrenal Tumors Staging System (2015): A United States Validation. The Journal of Clinical Endocrinology & Metabolism. 2024;109(11):e2084-e2089. doi:10.1210/clinem/dgae047

BibTeX
@article{Jannello2024,
  author = {Jannello, Letizia Maria Ippolita and Incesu, Reha-Baris and Morra, Simone and Scheipner, Lukas and Baudo, Andrea and de Angelis, Mario and Siech, Carolin and Tian, Zhe and Goyal, Jordan A and Luzzago, Stefano and Mistretta, Francesco A and Ferro, Matteo and Saad, Fred and Shariat, Shahrokh F and Chun, Felix K H and Briganti, Alberto and Tilki, Derya and Ahyai, Sascha and Carmignani, Luca and Longo, Nicola and de Cobelli, Ottavio and Musi, Gennaro and Karakiewicz, Pierre I},
  title = {The European Network for the Study of Adrenal Tumors Staging System (2015): A United States Validation},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  volume = {109},
  number = {11},
  pages = {e2084--e2089},
  doi = {10.1210/clinem/dgae047}
}
Kostenlos starten →